Transdermal Delivery of Proteins Using a Combination of Iontophoresis and Microporation
- 1 May 2014
- journal article
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 5 (5) , 525-536
Abstract
This study aimed to investigate transdermal delivery of proteins using combination of microporation and iontophoresis (ITP). Materials & methods & results: Delivery of model protein, Alexa Fluor 555 bovine serum albumin conjugate (AF-BSA) using ITP alone, microneedle (MN) alone, and ITP plus MN combination was assessed using confocal microscopy. Compared to MN alone, combination of MN plus ITP significantly increased skin's penetration depth of AF-BSA (300 vs 110 μm) and achieved lateral distribution of the model protein. Average fluorescence intensity quantified around each microchannel was 23.7-fold (8.2-fold, in vivo) higher for combination treatment compared with MN alone, in vitro. After 1 h in vitro permeation study, the unlabeled BSA amount delivered across skin was found to be 0, 1.4, 0.63 and 14 μg by passive, MN alone, ITP alone and ITP plus MN combination delivery, respectively.Keywords
This publication has 40 references indexed in Scilit:
- Chemical enhancer induced changes in the mechanisms of transdermal delivery of zinc oxide nanoparticlesBiomaterials, 2009
- Transdermal delivery of proteins mediated by non‐covalently associated arginine‐rich intracellular delivery peptidesExperimental Dermatology, 2007
- Theme Section: Transdermal Delivery of ProteinsPharmaceutical Research, 2007
- Transdermal Delivery of Cytochrome C—A 12.4 kDa Protein—Across Intact Skin by Constant–Current IontophoresisPharmaceutical Research, 2007
- Current status and future potential of transdermal drug deliveryNature Reviews Drug Discovery, 2004
- Stability and transdermal absorption of topical amphotericin B liposome formulationsInternational Journal of Pharmaceutics, 2004
- Development of Novel Drug Delivery System (DDS) Technologies for Proteomic-Based Drug DevelopmentBiological and Pharmaceutical Bulletin, 2004
- Modeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathwaysJournal of Controlled Release, 2003
- Transdermal Delivery of Antisense Oligonucleotides with Microprojection Patch (macroflux®) TechnologyPharmaceutical Research, 2001
- Translating Safety, Efficacy and Compliance into Economic Value for Controlled Release Dosage FormsPharmacoEconomics, 1994